Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A.

Abstract

The effect of a small dose of aclacinomycin-A (ACR) was examined in two patients with refractory anemia (RA) and two with refractory anemia with excess of blasts in transformation (RAEB-t). ACR (7 or 14 mg/m2) was given for 10 days in a 2-h per day drip infusion. Clinical symptoms and laboratory data improved in 3 of these 4 patients. In a patient with RA, marked increase in reticulocytes and elevation of the hemoglobin level from 6 to 9 g/dl was observed after two courses of ACR therapy. In two with RAEB-t, Auer's rod bearing cells disappeared in the bone marrow and megaloblastic change of the erythroblasts was diminished in one patient. Hemoglobin levels rose from 4.7 to 10 g/dl in one, and platelets and WBC increased in another. No effect was seen in a patient with RA. The cytoreductive effect of ACR was minor compared to the therapy with small dose of cytosine arabinoside (Ara-C). Therefore, ACR warrants further consideration for the treatment of patients with MDS.

• Authors: T Shibuya, E Morioka, S Taniguchi, N Ohhara, S Okamura, Y Niho
• Journal: Leukemia research (Leuk Res) Vol. 11 Issue 10 Pg. 851-4 ( 1987) ISSN: 0145-2126 [Print] England
• PMID: 3479662 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Naphthacenes
• Cytarabine
• Aclarubicin

Topics

• Aclarubicin
• Adult
• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Cytarabine (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy)
• Naphthacenes (therapeutic use)